Project Grant R01DA060239
- Federal Cooperative Agreement Summary George Washington University received a $2.1 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research evaluating oxytocin (OXT), an FDA-approved medication, as a novel therapeutic intervention for opioid-induced respiratory depression (OIRD). The research initiative, awarded July 1, 2025, with completion expected June 30, 2027, addresses the critical...
- This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
- OXYTOCIN AND DRUG EXTINCTION IN PRAIRIE VOLES PROJECT Florida State University received a $2.16 million Project Grant award dated August 15, 2025, from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research investigating the neurobiological mechanisms linking social environment and drug addiction. The research utilizes prairie voles as an animal model to examine how oxytocin—a neurochemical involved in social...
- The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
- The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...
- This Project Grant award, titled "DISSECTING THE MECHANISMS UNDERLYING FENTANYL-INDUCED CARDIORESPIRATORY DEPRESSION", is funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The award provides $671,732 to The Washington University to conduct research aimed at understanding the peripheral mechanisms underlying opioid-induced respiratory depression, a leading cause of opioid overdose deaths. The goal is to evaluate...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
- Federal Grant Award Summary Oregon Health & Science University received a $791,990 Project Grant award effective June 15, 2025, from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal mechanistic study examining reciprocal relationships between cannabis use, sleep, and hypothalamic-pituitary-adrenal (HPA) axis functioning. The three-year research initiative (completion date April 30, 2030) will enroll 60...
- Federal Grant Award Summary CALM-OSA Research Project Yale University received a $764,853 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with a completion date of May 31, 2030. This research project investigates the relationship between arousal threshold (ARTH)—an individual's propensity to awaken from respiratory stimuli—and treatment outcomes in obstructive sleep apnea (OSA)...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $450,000 in funding to Old Dominion University to investigate the relationship between disturbed sleep and the development of vulnerable atherosclerotic plaques. The primary objectives are to: 1) examine the role of NADPH-dependent oxidative stress in accelerating the formation of vulnerable atherosclerotic plaques in...
OXYTOCIN NEUROTRANSMISSION OVERCOMES SLEEP APNEA-RELATED OIRD HYPERSENSITIVITY - THIS PROPOSAL SEEKS TO UNCOVER THE BIOLOGICAL BASIS FOR WHY SLEEP APNEA PATIENTS ARE MORE SENSITIVE TO OPIOID- INDUCED RESPIRATORY DEPRESSION (OIRD) - THE PRIMARY CAUSE OF DEATH DUE TO OPIOID OVERDOSE. CLINICALLY, THERE IS A PRESSING NEED FOR NEW THERAPEUTICS TO COUNTER RESPIRATORY DEPRESSIVE EFFECTS OF OPIOIDS WITHOUT INTERRUPTING THEIR PAIN-KILLING ACTIONS AND WITHOUT CAUSING UNWANTED WITHDRAWAL EFFECTS. WE RECENTLY DISCOVERED THAT OXYTOCIN, AN ANALGESIC AND ANXIOLYTIC HORMONE AND NEUROTRANSMITTER PRODUCED IN A MAJOR APNEA-SENSITIVE RESPIRATORY AROUSAL HUB, THE PARAVENTRICULAR NUCLEUS OF THE HYPOTHALAMUS (PVH), CAN PREVENT AND REVERSE OIRD BY THE MOST LETHAL OPIOID FENTANYL. NOTABLY, OPIOID RECEPTOR BLOCKADE WITH NARCAN (NALOXONE, NLX) AND INTRANASAL OXYTOCIN BOTH IMPROVE SYMPTOMS OF OBSTRUCTIVE SLEEP APNEA. OUR CONCEPT IS THAT SLEEP APNEA PATIENTS HAVE DEFICIENT OXYTOCIN NEUROTRANSMISSION CAUSED BY AN EXCESS OF ENDOGENOUS OPIOIDS. THIS WOULD EXPLAIN WHY BOTH BLOCKING OPIOID RECEPTORS AND SUPPLEMENTING OXYTOCIN IMPROVE SLEEP APNEA SYMPTOMS. OUR CENTRAL HYPOTHESIS IS THAT DEFICIENT OXYTOCIN NEUROTRANSMISSION FROM THE PVH TO RESPIRATORY NEURONS LEAVES THE RESPIRATORY NETWORK UNABLE TO MOUNT A SUFFICIENT VENTILATORY DEFENSE RESPONSE TO EFFECTIVELY COMBAT OIRD. THIS OXYTOCIN DEFICIENCY IS MODELED AS AN ADAPTIVE RESPONSE TO SLEEP APNEA THAT PREVENTS HYPERVENTILATION THAT WOULD OTHERWISE RESULT FROM TONIC HYPERACTIVITY OF HYPOXIA-SENSITIVE CAROTID BODY CHEMORECEPTORS. TONIC CHEMORECEPTOR ACTIVITY IS A WELL-RECOGNIZED RESPONSE TO SLEEP APNEA THAT CONTRIBUTES TO DEVELOPMENT OF HYPERTENSION. OUR WORKING MODEL HOLDS THAT ADAPTIVE UPREGULATION OF PVH ENDOGENOUS OPIOIDS BY SLEEP APNEA BECOMES MALADAPTIVE WHEN SLEEP APNEA PATIENTS TAKE AN ANALGESIC OR ILLICIT DOSE OF OPIOID, LEADING TO OIRD HYPERSENSITIVITY. ACCORDING TO OUR MODEL, PVH ENDOGENOUS OPIOID UPREGULATION CONSTITUTES HIT #1 IN A DOUBLE- HIT SCENARIO. ADMINISTRATION OF EXOGENOUS OPIOID (I.E., FENTANYL) CONSTITUTES HIT #2, TRIGGERING EXAGGERATED OIRD. SPECIFIC AIMS TEST THE EXTENT TO WHICH EXPERIMENTAL UPREGULATION OF PVH ENDOGENOUS OPIOIDS IS SUFFICIENT IN NORMOXIC MICE TO MIMIC OIRD HYPERSENSITIVITY IN MICE EXPOSED TO OUR CHRONIC INTERMITTENT HYPERCAPNIC HYPOXIA (CIHH) MODEL OF SA. WE WILL ALSO INVESTIGATE MECHANISMS WHEREBY OXYTOCIN RECEPTOR SIGNALING OCCLUDES THE INHIBITOR ACTION OF OPIOIDS ON RESPIRATORY NEURONS WHILE ALSO TESTING WHETHER FENTANYL CIHH OIRD HYPERSENSITIVITY IS NORMALIZED BY PVH OPIOID RECEPTOR BLOCKADE, ELIMINATING HIT #1. STUDIES WILL FURTHER DEFINE THE CONTRIBUTION OF ENDOGENOUS PVH OPIOIDS IN MASKING SLEEP APNEA-RELATED RESPIRATORY HYPERDRIVE AND IN BLUNTED OXYTOCIN EXCITATION OF RESPIRATORY NEURONS. OPTO- AND CHEMOGENETIC EXCITATION AND INHIBITION STUDIES WILL REVEAL THE CAPACITY OF ACUTE AND PROLONGED EXCITATION AND INHIBITION OF PVH OXYTOCIN NEURONS TO PRODUCE EXAGGERATED OIRD IN NORMOXIC MICE AND MITIGATE OIRD HYPERSENSITIVITY IN CIHH MICE. FINDINGS WILL YIELD NEW TRANSLATIONAL INFORMATION ABOUT A POWERFUL OXYTOCINERGIC NEURAL CIRCUIT PREVIOUSLY UNKNOWN TO OPIOID RESUSCITATION RESEARCH AND REVEAL NEW TARGETS TO PREVENT SLEEP APNEA RELATED OIRD HYPERSENSITIVITY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $540.5k | 5/23/25 | ||
| Not listed | $581.9k | 7/19/24 | ||
| Not listed | $581.9k | 7/19/24 |